Lv1
30 积分 2025-06-21 加入
FDA new drug approvals in Q3 2025
1个月前
已完结
Preliminary Safety, Pharmacological and Efficacy Data from Patients with Relapsed or Refractory B-Cell Malignancies Treated with the ICP-248, a Next Generation BCL2 Inhibitor
3个月前
已关闭
Efficacy and tolerability of mesutoclax monotherapy in Relapsed/Refractory Mantle Cell Lymphoma patients: High remission rates even in prior BTKi-refractory patients
3个月前
已关闭
Venetoclax efficacy on acute myeloid leukemia is enhanced by the combination with butyrate
3个月前
已关闭
Venetoclax: First Global Approval
3个月前
已完结
Tivozanib in relapsed or refractory advanced renal cell carcinoma: a focus on US approval
3个月前
已完结
Tivozanib: A New Hope for Treating Renal Cell Carcinoma
3个月前
已完结
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study
3个月前
已完结
2021 FDA approvals
3个月前
已完结
Impact of Belzutifan on Pancreatic Cystic Lesions and Neuroendocrine Tumors in Patients with Von Hippel-Lindau Disease
3个月前
已关闭
皖公网安备34019202002308
